Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.59
-0.0400-1.10%
Volume:436.76K
Turnover:1.59M
Market Cap:1.18B
PE:-2.80
High:3.68
Open:3.66
Low:3.59
Close:3.63
Loading ...

Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
28 Feb

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 17.49% in Pre-Market After Q4 Earnings Miss and Disappointing Guidance

Stock Track
·
28 Feb

Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ...

GuruFocus.com
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Iovance Biotherapeutics Inc : Baird Cuts Target Price to $20 From $24

THOMSON REUTERS
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 16.54% as Q4 Earnings and Guidance Disappoint

Stock Track
·
28 Feb

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

Iovance Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 7.97% After Hours on Disappointing Q4 Earnings and Guidance

Stock Track
·
28 Feb

Iovance Biotherapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

Iovance Biotherapeutics Q4 2024 GAAP EPS $(0.26) Beats $(0.27) Estimate, Sales $73.700M Beat $72.393M Estimate

Benzinga
·
28 Feb

BRIEF-Iovance Biotherapeutics Q4 Net Income USD -78.559 Million

Reuters
·
28 Feb

Iovance Biotherapeutics Inc: Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M

THOMSON REUTERS
·
28 Feb